SG Americas Securities LLC Acquires 963 Shares of Icosavax, Inc. (NASDAQ:ICVX)

SG Americas Securities LLC raised its position in Icosavax, Inc. (NASDAQ:ICVX) by 6.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 15,502 shares of the company’s stock after purchasing an additional 963 shares during the period. SG Americas Securities LLC’s holdings in Icosavax were worth $244,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of ICVX. Price T Rowe Associates Inc. MD raised its position in Icosavax by 82.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,342,470 shares of the company’s stock worth $19,152,000 after buying an additional 1,506,613 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Icosavax by 34.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,463,525 shares of the company’s stock worth $35,441,000 after buying an additional 1,148,465 shares during the last quarter. FMR LLC raised its position in Icosavax by 22.9% in the 1st quarter. FMR LLC now owns 6,003,002 shares of the company’s stock worth $34,817,000 after buying an additional 1,117,631 shares during the last quarter. Vanguard Group Inc. raised its position in Icosavax by 96.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,898,287 shares of the company’s stock worth $14,712,000 after buying an additional 931,859 shares during the last quarter. Finally, BlackRock Inc. raised its position in Icosavax by 36.3% in the 2nd quarter. BlackRock Inc. now owns 1,786,140 shares of the company’s stock worth $17,736,000 after buying an additional 475,777 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Guggenheim reissued a “neutral” rating on shares of Icosavax in a research report on Tuesday, January 2nd.

Icosavax Stock Performance

Shares of NASDAQ:ICVX opened at $15.31 on Thursday. Icosavax, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $16.10. The firm has a fifty day moving average price of $15.31 and a 200 day moving average price of $12.55. The firm has a market cap of $766.88 million, a price-to-earnings ratio of -6.90 and a beta of 1.28.

Insider Buying and Selling at Icosavax

In other Icosavax news, CEO Adam K. Simpson sold 15,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $15.29, for a total transaction of $229,350.00. Following the completion of the transaction, the chief executive officer now owns 358,657 shares in the company, valued at $5,483,865.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 30.59% of the stock is owned by company insiders.

Icosavax Company Profile

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.